13F reference period
Q2 2026
Security Snapshot
Coya Therapeutics, Inc. - Common Stock, $0.0001 par value per share (COYA) Institutional Ownership
CUSIP: 22407B108
13F Institutional Holders and Ownership History from Q4 2022 to Q3 2026
Institutions Reporting
54
Shares (Excl. Options)
7.78M
Full value: 7,775,612 · shares · 30 Jun 2026Price
$5.85
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- COYA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 7,775,612
- Total 13F value
- $45,450,388
- Portfolio coverage rank
- 0%
- Share change
- -353,191
- Value change
- -$1,705,330
- Number of holders
- 54
- Shares outstanding
- 23,172,091
- SEC-reported price per share
- $4.81
- Insider filing price
- $4.81
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- COYA - Coya Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 22407B108.
- 54 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 57 to 54 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$32.05M
Full value: $32,048,898 · USD · 31 Mar 2026.$45.45M
Full value: $45,450,388 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 54 institutions filings for Q2 2026.
Security key
22407B108
13F reference period
Q2 2026
13F holders
54
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
COYA full holder history
Coya Therapeutics, Inc. SEC filings
Coya Therapeutics, Inc. company facts
Coya Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 22407B108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
COYA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Dr. Reddy's Laboratories, Inc. | 9.7% | $10,727,271 | 2,272,727 | Dr. Reddy's Laboratories, Inc. | 30 Jan 2026 | |||
| DME Capital Management, LP | 9.9% | $10,783,903 | 1,651,440 | DME Advisors GP, L.L.C. | 31 Dec 2024 | |||
| VANGUARD GROUP INC | 4.3% | $5,215,012 | 899,140 | The Vanguard Group | 31 Dec 2025 | |||
| HIRSCHMAN ORIN | 3.3% | -40% | $4,473,372 | -$2,009,428 | 764,679 | -31% | Orin Hirschman | 30 Jun 2026 |
As of 30 Jun 2026,
54
institutional investors reported holding
shares of
Coya Therapeutics, Inc. - Common Stock, $0.0001 par value per share (COYA).
This represents
34%
of the company’s total
outstanding shares.
7.78M
Full value: 7,775,612 · shares · 30 Jun 202623.17M
Full value: 23,172,091 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
32%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| DME Capital Management, LP | 10% | 2,335,540 | 0% | 0.35% | $13,662,909 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 842,220 | -0.32% | 0% | $4,926,987 |
| Alyeska Investment Group, L.P. | 3.5% | 800,000 | 0% | 0.01% | $4,680,000 |
| AIGH Capital Management LLC | 2.7% | 631,912 | -35% | 0.33% | $3,696,685 |
| CM Management, LLC | 1.7% | 400,000 | +6.7% | 1.5% | $2,340,000 |
| PRIVATE MANAGEMENT GROUP INC | 1.7% | 384,217 | +4.1% | 0.06% | $2,247,669 |
| MARSHALL WACE, LLP | 1.1% | 249,793 | +11% | 0% | $1,461,289 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.98% | 228,243 | -2.2% | 0% | $1,335,507 |
| RENAISSANCE TECHNOLOGIES LLC | 0.83% | 192,986 | +86% | 0% | $1,128,968 |
| Prosight Management, LP | 0.73% | 170,000 | -60% | 0.17% | $994,500 |
| DIMENSIONAL FUND ADVISORS LP | 0.67% | 155,917 | +63% | 0% | $913,036 |
| VANGUARD FIDUCIARY TRUST CO | 0.56% | 129,551 | -7.4% | 0% | $757,873 |
| JONES FINANCIAL COMPANIES LLLP | 0.48% | 110,910 | +147% | 0% | $610,005 |
| BlackRock, Inc. | 0.44% | 102,408 | +24% | 0% | $599,087 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.44% | 101,330 | 0% | 0.04% | $592,781 |
| JBF Capital, Inc. | 0.43% | 100,006 | 0% | 0.08% | $585,035 |
| ROYAL BANK OF CANADA | 0.4% | 93,414 | +598% | 0% | $546,000 |
| MORGAN STANLEY | 0.35% | 82,106 | -4.2% | 0% | $480,320 |
| STATE STREET CORP | 0.34% | 79,813 | 0% | 0% | $466,906 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.26% | 61,006 | +55% | 0% | $356,885 |
| NORTHERN TRUST CORP | 0.19% | 45,072 | +12% | 0% | $263,671 |
| XTX Topco Ltd | 0.18% | 41,401 | -13% | 0% | $242,196 |
| ADAR1 Capital Management, LLC | 0.18% | 40,900 | 0% | 0.01% | $239,265 |
| Long Corridor Asset Management Ltd | 0.17% | 38,766 | 0% | 0.07% | $226,781 |
| Cetera Investment Advisers | 0.15% | 34,000 | +13% | 0% | $198,900 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
16
Headline period
Q2 2026
Rows shown
1-16 of 16
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 2,117,164 | $10,607,323 | -$366,056 | $5.01 | 20 |
| 2026 Q2 | 7,775,612 | $45,450,388 | -$1,705,330 | $5.85 | 54 |
| 2026 Q1 | 8,132,603 | $32,048,898 | -$1,369,168 | $3.94 | 57 |
| 2025 Q4 | 7,939,025 | $46,046,406 | +$18,480,971 | $5.80 | 58 |
| 2025 Q3 | 4,755,804 | $27,110,326 | +$1,543,439 | $5.70 | 35 |
| 2025 Q2 | 4,484,686 | $25,787,239 | -$1,022,977 | $5.75 | 33 |
| 2025 Q1 | 4,662,591 | $30,167,676 | +$1,480,613 | $6.47 | 26 |
| 2024 Q4 | 4,444,580 | $25,467,940 | +$6,454,839 | $5.73 | 26 |
| 2024 Q3 | 3,315,161 | $21,385,210 | +$304,078 | $6.45 | 19 |
| 2024 Q2 | 3,268,292 | $19,805,900 | -$932,467 | $6.06 | 19 |
| 2024 Q1 | 3,339,060 | $33,123,748 | +$5,311,359 | $9.92 | 19 |
| 2023 Q4 | 2,822,037 | $20,644,859 | +$10,288,077 | $7.41 | 20 |
| 2023 Q3 | 1,416,355 | $5,449,280 | +$229,488 | $3.84 | 14 |
| 2023 Q2 | 1,351,642 | $5,500,530 | +$1,016,457 | $4.07 | 13 |
| 2023 Q1 | 1,101,849 | $4,368,596 | +$41,079 | $3.97 | 7 |
| 2022 Q4 | 1,091,417 | $5,156,354 | +$5,156,354 | $4.74 | 4 |